A Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of zidebactam Administered as Multiple IV Doses in Healthy Human Volunteers

Trial Profile

A Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of zidebactam Administered as Multiple IV Doses in Healthy Human Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 12 May 2017

At a glance

  • Drugs Zidebactam (Primary)
  • Indications Gram-negative infections
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 12 May 2017 New trial record
    • 25 Apr 2017 Results assessing safety, tolerability and pharmacokinetics of Zidebactam and WCK 5222 using patient data from two double blind MAD studies (See CTPs 284673 and 284682), presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top